Cathrin BriskenCathrin Brisken, MD, PhD, is Associate Professor of Life Sciences at the Swiss Federal Institute of Technology Lausanne (EPFL). Dr. Brisken is internationally recognized for her work on endocrine control of mammary gland development and breast carcinogenesis.
Dr. Brisken received her MD and her PhD degree in Biophysics from the Georg August University of Göttingen, Germany. She completed her postdoctoral work in cancer biology with Dr. R.A. Weinberg at the Whitehead Institute of Biomedical Research in Cambridge, MA, USA. She previously held appointments at the Cancer Center of the Massachusetts General Hospital, Harvard Medical School, Boston and the Swiss Institute for Experimental Cancer Research (ISREC).
Research in Dr. Brisken’s laboratory focuses on the cellular and molecular underpinnings of estrogen and progesterone receptor signaling in the breast and the respective roles of these hormones and hormonally active compounds in carcinogenesis. The aim is to understand how recurrent exposures to endogenous and exogenous hormones contribute to breast carcinogenesis in order to better prevent and treat the disease. The laboratory has pioneered in vivo approaches to genetically dissect the role of the reproductive hormones in driving mouse mammary gland development and shown how they control intercellular communication. Dr. Brisken’s group has developed ex vivo and humanized mouse models using patient samples to study hormone action in human tissues in normal settings and during disease progression.
Dr. Brisken is member of the International Breast Cancer Study Group (IBCSG) Biological Protocol Working Group. She served as Dean of EPFL Doctoral School (more than 2000 PhD students in 18 PhD programs), as member of the Hinterzartener Kreis, the oncology think-tank associated with the German Science Foundation, and numerous Swiss, European, and AACR committees. She co-founded the International Cancer Prevention Institute.
Sandrine GerberSandrine Gerber studied chemistry at the "Ecole Nationale Supérieure de Chimie de Paris" in France, where she obtained a diploma of chemical engineer in 1993. The same year she obtained a DEA (Master degree) of organic chemistry at the University Pierre et Marie Curie (Paris VI, France). From 1993 to 1996 she did a PhD in organic chemistry under the supervision of Prof. Jean-Pierre Genêt at the Ecole Nationale Supérieure de Chimie de Paris. In 1996, she moved to University of Lausanne for a post-doctoral stay under the supervision of Prof. Pierre Vogel. In 1998, she was appointed Maître-Assistante at the Institute of Organic Chemistry in the University of Lausanne. In 2003, she obtained the habilitation to direct research from the University Pierre et Marie Curie (Paris VI, France). The same year, she was appointed scientific adjunct at the EPFL and senior scientist (Maître d'Enseignement et de Recherche) in 2006. In December 2014, she was promoted to titular professor. Since September 2007, Sandrine Gerber is deputy to the director of the Institute of Chemical Sciences and Engineering (ISIC). She is also member of the Board of Directors of the Swiss Chemical Society. Since 2007, Sandrine Gerber is part-time lecturer at the university of Fribourg. She was awarded the Prize Eugene Schueller in 1997, the Prize Dufour for prospective organic chemistry in 2005 and the Werner Prize 2010. She also received a special mention in recognition of exceptional quality of pedagogic competencies in the teaching of basic sciences, given by the Direction of the School of Biology and Medicine from the University of Lausanne, in 2013. In October 2018, she will receive the Prize for Excellence in Teaching from the section of Chemistry and Chemical Engineering.
Daniel ConstamDaniel Constam received his doctoral degree in Natural Sciences from ETH Zürich in the neuroimmunology group of Adriano Fontana (1993). For postdoctoral studies, he joined the laboratory of Elizabeth Robertson as an EMBO fellow at Harvard University to characterize proprotein convertase (PC) functions in mouse models of early embryogenesis (1994-1999). As an ISREC group leader (>2000) and Associate Professor at EPFL (>2007), he initially continued to study pluripotency and lineage differentiation during development and found that several secreted PCs jointly regulate cell-cell adhesion and TGFβ signaling pathways at the cross-roads of stem cell and cancer biology. To map the proteolytic activity of PCs and their relative distribution in exocytic or endocytic vesicles, his lab developed PC-specific FRET sensors for high resolution live imaging in normal cells and in tumour-host interactions. His studies on TGFβ signaling also identified the RNA-binding protein Bicc1 and its self-polymerization in membrane-less organelles as regulators of mRNA translation and cell metabolism that cooperate with primary cilia to prevent cystic growth in renal tubules and in pancreatic and bile ducts.
Yann BarrandonYann Barrandon graduated in Medicine in Paris where he also trained as a dermatologist and completed his PhD on the long term cultivation of human haematopoietic stem cells in 1982 under the direction of Dr. Catherine Dresch (Centre Hayem, St Louis Hospital). He worked as a post-doctoral fellow (1982-1983) with Pr. Marvin Karasek in the Department of Dermatology at Stanford University CA, and then with Pr. Howard Green, a pioneer in cell therapy, in the Department of Molecular and Cellular Physiology at Harvard Medical School (1983-1990). During this period, he participated in the world's first transplantations of epidermal stem cells on extensive third degree wounds and contributed several seminal findings including the demonstration of stem cells in cultures of human keratinocytes (PNAS 1987), and that human keratinocyte stem cells could be efficiently transduced by retroviral vectors (Science 1987), in collaboration with Richard Mulligan at the Whitehead Institute for Biomedical Research (Massachussets Institute of Technology, Cambridge, USA). He has also participated to the transfer of the stem cell technology from Harvard University to a spin off biotechnology company, now part of Genzyme Corp.
He returned to France in 1990 as Director of Research at the INSERM and Head of Lab at the Ecole Normale Supérieure, Paris. During this period, he demonstrated the presence of multipotent clonogenic stem cells in hair follicles (Cell 1994, 2001) and successfully brought stem cells from bench to bedside demonstrating the usefulness of a fibrin matrix to transplant epidermal stem cells. (Transplantation, 2000). Following his move to Lausanne, Yann Barrandon has shown that oligopotent stem cells are present in the mammalian cornea (Nature 2008), challenging previous dogma. He has also contributed to the characterisation of several skin diseases (Nature Genetics, 1993a, 1993b, 2000, 2005) and towards gene therapy of dystrophic epidermolysis bullosa. He is a partner in several EEC stem cell consortia (FP6: Therapeuskin and EuroStemCell, FP7: EuroSyStem, OptiStem, BetaCellTherapy).
Current research targets the role of small microenvironmental variations on stem cell behavior, and exploring the potency of stem cells of stratified epithelia (skin, esophagus, ocular surface) and of thymic epithelial cells. The lab is also involved in understanding the factors that regulate stem cell engraftment to improve epithelial cell therapy. An important aspect of the research aims at setting up a pilot clinical trial to demonstrate the feasibility of ex vivo gene therapy to treat Dystrophic Epidermolysis Bullosa, a rare but horrendous congenital disease of the skin that results in continuous blistering of the skin, chronic wounds, fusion of fingers and development of carcinoma.
Yann Barrandon was a member of the Faculty Council of the EPFL School of Life Sciences 2006-2008, of the Board of Swiss Stem Cell Network, 2004-2009, and is a member of the EPFL Ethics Committee since 2008. He is a reviewer for major scientific journals and for major granting agencies abroad. He is a member of the board of Directors of the International Society for Differentiation (ISD) and of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) and was a Member of the Board of Directors of the European Tissue Repair Society, 1990-1995. He was elected as EMBO member in 2009.
He has given over 300 invited conferences and seminars worldwide on the biology and the therapeutic use of cutaneous stem cells including:
Gordon Research Conferences, Tissue Repair and Regeneration, June 2005, New London, USA,
Keystone Symposia on Stem Cells, April 2006, Whistler, Canada
Keystone Symposia, Stem Cell Interactions with their Microenvironmental Niche, March 2007, Keystone, USA
Keystone Symposia, Stem Cell Niche Interactions, April 2009, Whistler, Canada
Gordon Research Conferences, Epithelial Stem Cells, June 2009, Les Diablerets, Switzerland
7th Meeting of the International Society Stem Cell Research, July 2009, Barcelona, Spain
16th International Society for Developmental Biologists, Edinburgh, Scotland, UK, Sept 2009
Yann Barrandon has given multiple media interviews and participated to different reportages:
LCI, TF1, France 2, France 3, RSR (Radio Suisse Romande), TSR (Television Suisse Romande), and articles in newspapers: Figaro, La Croix, Le Temps, LHebdo, Le Nouvelliste, etc. He was also a participant in the movie A Stem Cell Story, EuroStemCell, Best TV/video production, Tromsø Science Media Festival; Best short film, Scinema (Australia); In competition, Science Film Festival (Bangkok), BaKaFORUM 2007, Vedere la Scienza
He organized the second EuroStemCell international conference Advances in Stem Cell Research supported by the EMBO and held in Lausanne 8-10 September 2006. He regularly participates as faculty to the EEC funded Stem Cell Summer School held in Hydra Greece since 2005.
Freddy RadtkeFreddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences
Douglas HanahanDouglas Hanahan, born in Seattle, Washington, USA, received a bachelors degree in Physics from MIT (1976), and a Ph.D. in Biophysics from Harvard (1983). He worked at Cold Spring Harbor Laboratory in New York (1978-88) initially as a graduate student and then as a group leader. From 1988-2010 he was on the faculty of the Department of Biochemistry & Biophysics at UCSF in San Francisco. He has been elected to the American Academy of Arts & Sciences (2007), the Institute of Medicine (USA) (2008), the US National Academy of Science (2009), and EMBO (2010). In 2011, Hanahan received an honorary degree from the University of Dundee (UK).
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Paul Joseph DysonPaul Dyson joined the Institute of Chemical Sciences and Engineering at the EPFL in 2002 where he heads the Laboratory of Organometallic and Medicinal Chemistry and between 2008 and 2016 chaired the Institute. He has won several prizes including the Werner Prize of the Swiss Chemical Society in 2004, the Award for Outstanding Achievements in Bioorganometallic Chemistry in 2010, the Centennial Luigi Sacconi Medal of the Italian Chemical Society in 2011, the Bioinorganic Chemistry Award of the Royal Society of Chemistry in 2015, the European Sustainable Chemistry Award of the European Chemical Society in 2018 and the Green Chemistry Award from the Royal Society of Chemistry in 2020. He is also a Clarivate Highly Cited Researcher and has an H-index >110 (web of science and google scholar). He was elected a Fellow of the Royal Society of Chemistry in 2010, a Fellow of the European Academy of Science in 2019 and a life-long fellow of the American Association for the Advancement of Science in 2020. Over the years he has held visiting professorships at the University of Bourgogne, University of Pierre et Marie Curie, University of Vienna, University of Rome Tor Vergara, Chimie Paristech and Shangai Jiao Tong University.Since 2016 he has been Member of the Council of the Division of Mathematics, Natural and Engineering Sciences at the Swiss National Science Foundation.Between 2016-2021 he has been Member of the Council of the Division of Mathematics, Natural and Engineering Sciences at the Swiss National Science Foundation. In 2021 he was appointed Dean of the Faculty of Basic Sciences.
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Maria del Carmen Sandi PerezACADEMIC POSITION:
Professor, Director of the Laboratory of Behavioral Genetics, Brain Mind Institute, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland.
EDUCATION:
BS MS Salamanca, Spain, 1984
PhD Cajal Institute, CSIC, and University Autonoma of Madrid, Spain, 1988
PROFESSIONAL EXPERIENCE:
Postdoc at INSERM, Bordeaux, France, and Cajal Institute Madrid, Spain, 1989-1990
Postdoc at the Open University, UK, 1991-1992, 1996
Research Associate, Cajal Institute, CSIC, Madrid, 1993-1995
Associate Professor Tenured, UNED University, Madrid, 1996-2003
Sabbatical Professor, University of Bern, Switzerland, 2002-2003
Assistant Professor Tenure-Track, EPFL, 2003-2007
Associate Professor Tenured, EPFL, 2007-2012
Full Professor, EPFL, 2012-
Director, Brain Mind Institute, EPFL, 2012-
PRINCIPAL BOARDS:
President, European Brain and Behavior Society (EBBS), 2009-2012
Editor-in-Chief Frontiers in Behavioral Neuroscience
Member of Scientific Advisory Panel, European College Neuropsychopharmacology (ECNP)
Member of the European Dana Alliance for the Brain (EDAB)
Associate Editor Frontiers in Neuroscience
Editorial Board Member Neurobiology of Learning and Memory
Editorial Board Member Journal of Psychiatry Research
Editorial Board Member Stress
Editorial Board Member Biology of Mood and Anxiety Disorders
Editorial Board Member Neuroscience and Biobehavioral Reviews